Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

NCT06719973 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study was terminated due to decision made not to proceed with the clinical trial DDRiver 521, that has not yet commenced enrolment, for strategic reasons.

Conditions

Advanced Solid Tumors

Interventions

DRUG: M9466
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Atezolizumab
DRUG: M9446
DRUG: M9446
DRUG: Carboplatin

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

[object Object]